TOCQUEVILLE ASSET MANAGEMENT L.P. - EIGER BIOPHARMACEUTICALS INC ownership

EIGER BIOPHARMACEUTICALS INC's ticker is EIGR and the CUSIP is 28249U105. A total of 51 filers reported holding EIGER BIOPHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
TOCQUEVILLE ASSET MANAGEMENT L.P. ownership history of EIGER BIOPHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$15,578
-56.7%
51,0750.0%0.00%
-100.0%
Q2 2023$35,957
-21.5%
51,0750.0%0.00%0.0%
Q1 2023$45,809
-24.0%
51,0750.0%0.00%0.0%
Q4 2022$60,269
-88.8%
51,075
-28.6%
0.00%
-90.9%
Q3 2022$539,000
+36.8%
71,575
+14.4%
0.01%
+57.1%
Q2 2022$394,000
-23.2%
62,575
+1.3%
0.01%
-12.5%
Q1 2022$513,000
+67.1%
61,775
+4.6%
0.01%
+100.0%
Q4 2021$307,000
-21.3%
59,075
+1.3%
0.00%
-33.3%
Q3 2021$390,000
-11.8%
58,325
+12.3%
0.01%0.0%
Q2 2021$442,000
-5.6%
51,925
-1.9%
0.01%
-14.3%
Q1 2021$468,000
-41.4%
52,925
-18.5%
0.01%
-46.2%
Q4 2020$798,000
+39.8%
64,925
-7.5%
0.01%
+18.2%
Q3 2020$571,000
-4.0%
70,175
+13.2%
0.01%
-8.3%
Q2 2020$595,000
+53.0%
61,975
+8.3%
0.01%
+20.0%
Q1 2020$389,000
-48.7%
57,225
+12.5%
0.01%
-9.1%
Q4 2019$758,000
+104.3%
50,875
+40.6%
0.01%
+120.0%
Q3 2019$371,000
+2.2%
36,175
+5.6%
0.01%0.0%
Q2 2019$363,000
+9.3%
34,250
+44.2%
0.01%
+25.0%
Q1 2019$332,000
+23.9%
23,750
-9.9%
0.00%0.0%
Q4 2018$268,000
+32.0%
26,350
+55.9%
0.00%
+33.3%
Q3 2018$203,00016,9000.00%
Other shareholders
EIGER BIOPHARMACEUTICALS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Telemetry Investments, L.L.C. 135,848$2,024,0006.74%
INTERWEST VENTURE MANAGEMENT CO 764,918$11,397,0004.91%
Knoll Capital Management, LLC 350,238$5,219,0003.85%
683 Capital Management, LLC 1,850,000$27,565,0003.15%
Soleus Capital Management, L.P. 205,407$3,060,0002.95%
Broadfin Capital, LLC 1,236,368$18,422,0002.47%
P.A.W. CAPITAL CORP 144,000$2,146,0002.29%
MANGROVE PARTNERS IM, LLC 847,284$12,625,0001.85%
Corriente Advisors, LLC 203,898$3,038,0001.63%
Trellus Management Company, LLC 63,850$951,0001.59%
View complete list of EIGER BIOPHARMACEUTICALS INC shareholders